This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohyama, T.
Right arrow Articles by Isono, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohyama, T.
Right arrow Articles by Isono, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2004, p. 319-322, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.319-322.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

FKS1 Mutations Responsible for Selective Resistance of Saccharomyces cerevisiae to the Novel 1,3-ß-Glucan Synthase Inhibitor Arborcandin C

Takao Ohyama,* Shunichi Miyakoshi, and Fujio Isono

Lead Discovery Research Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo 140-8710, Japan

Received 7 August 2003/ Returned for modification 11 September 2003/ Accepted 26 September 2003


arrow
ABSTRACT
 
Arborcandin C is a novel antibiotic with potent antifungal activity that inhibits 1,3-ß-glucan synthase in fungi. We examined spontaneous Saccharomyces cerevisiae mutants which are selectively resistant to arborcandin C and revealed that a single amino acid replacement in Fks1p of Asn470 with Lys or of Leu642 with Ser confers selective resistance on Fks1p mutants.


arrow
INTRODUCTION
 
The 1,3-ß-glucan polymer is a major component of the cell wall in yeast and filamentous fungi (11) and is synthesized by 1,3-ß-glucan synthase (GS). In Saccharomyces cerevisiae, GS consists of at least two subunits: a putative catalytic subunit encoded by related genes FKS1 and FKS2 (7, 10) and a regulatory subunit, a GTP-bound protein encoded by RHO1 (16). Several types of GS inhibitors, such as echinocandins (5, 13), papulacandins (20), and FR901469 (8), have been identified. GS inhibitors are a new class of antifungal antibiotics with clinical significance because of their strong fungicidal activity and low toxicity (1, 3).

Arborcandins are recently isolated cyclic lipopeptides which inhibit GS from Candida albicans and Aspergillus fumigatus (14) and which also have growth-inhibitory activity (14). Although we reported that arborcandin C noncompetitively inhibited GS (14), the molecular target of the inhibition still remains to be elucidated. In this study, we isolated selective arborcandin C-resistant S. cerevisiae mutants with antibiotic-resistant-GS activity and revealed that two single-amino-acid mutations in Fks1p conferred selective resistance to arborcandin C.

Standard procedures were used for DNA manipulations (17). Genetic manipulations for yeast were carried out as described previously (9). Yeast strains and plasmids used in this study are listed in Table 1. All yeast strains were derivatives of S. cerevisiae YPH250 (18). Yeast cells were grown either in YPDAU medium (2% peptone, 1% yeast extract, 20 µg of adenine sulfate/ml, 20 µg of uracil/ml, 2% glucose) or SD medium (9) supplemented appropriately. FKS1 was cloned by screening the genomic DNA library of the wild-type strain (YPH250) for complementing fks1{Delta}::LEU2 on SD medium containing 1 µg of FK506/ml. An arborcandin C resistance gene was cloned by screening the genomic DNA libraries of the arborcandin C-resistant mutants ACR79-5 and ACR1A3 for genes that conferred growth in SD medium containing 5 µg of arborcandin C/ml on YPH250. The DNA sequence was determined by automated DNA sequencer model ABI3700 with a dye terminator cycle sequencing kit (Applied Biosystems).


View this table:
[in this window]
[in a new window]
 
TABLE 1. Yeast strains and plasmids used in this study

Growth inhibition was determined by the broth microdilution method in a 96-well microplate using YPDAU medium. Briefly, 104 yeast cells were inoculated into 150 µl of medium in each well and incubated at 30°C for 16 to 24 h in the presence or absence of GS inhibitors. The optical density at 595 nm of the exponentially growing culture was measured by microplate reader (ARVOsx; Perkin-Elmer).

Preparation and measurement of activity of GS from wild-type and mutant S. cerevisiae strains were performed according to the procedure described by Inoue et al. (10) and Cabib and Kang (4), respectively. The solubilized membrane fraction (10) was used as GS.


arrow
Isolation of selective arborcandin C-resistant mutants.
 
Arborcandin C is structurally different from echinocandins and papulacandins (14). To examine whether arborcandin C has a molecular target different from those of known GS inhibitors, we took a genetic approach. Spontaneously resistant S. cerevisiae mutants were isolated at a concentration of 1 µg of arborcandin C/ml on a YPDAU medium plate. We selected two mutants, ACR79-5 and ACR1A3, which are resistant only to arborcandin C, not to any other type of GS inhibitors, for further study. As the echinocandin-type and papulacandin-type inhibitors, we used pneumocandin A0 (2) and F-10748 C1 (15), respectively. As shown in Table 2, both mutants were 100-fold more resistant to arborcandin C than the parental wild-type strain and there was a modest change in the susceptibility to pneumocandin A0 and F-10748 C1. We did not observe significant differences between the wild-type strain and the mutants in their phenotypes, such as their cell morphology and calcofluor white sensitivity phenotypes, which reflect structural changes in the cell wall (data not shown).


View this table:
[in this window]
[in a new window]
 
TABLE 2. Susceptibilities of selective arborcandin C-resistant mutants to GS inhibitors

To determine whether the selective resistance of the mutants to arborcandin C was due to a change of sensitivity of GS, the sensitivity of GS from the mutants was tested. As shown in Table 3, GS from either of the resistant mutants was highly resistant to arborcandin C. The 50% inhibitory concentration of arborcandin C against the mutant's GS was more than 100-fold higher than that of arborcandin C against the wild-type enzyme. On the other hand, the sensitivity of both mutant enzymes to the other types of GS inhibitors tested was not significantly changed. These results suggested that the selective resistance of the mutants was due to the selective resistance of GS.


View this table:
[in this window]
[in a new window]
 
TABLE 3. Sensitivity of GS from selective arborcandin C-resistant mutants to GS inhibitors


arrow
Cloning of mutated genes responsible for selective arborcandin C resistance.
 
To identify the mutated genes in ACR79-5 and ACR1A3, we screened the genomic DNA library of each mutant using the centromere-type vector (pCE112) for plasmids conferring arborcandin C resistance on the wild-type strain. Four and three arborcandin C-resistant colonies were isolated by the transformation with the libraries of ACR79-5 and ACR1A3, respectively. All plasmid DNAs recovered from the resistant transformants conferred arborcandin C resistance (data not shown). Partial sequence analysis of the plasmids revealed that the minimum region conferring arborcandin C resistance from both the mutants contained an FKS1 locus as a complete open reading frame (data not shown). Therefore, it was strongly suggested that the gene mutated in both the resistant mutants was FKS1.


arrow
Mutation of Asn470 to Lys or Leu642 to Ser in Fks1p confers selective resistance to arborcandin C.
 
By DNA sequence analysis of the FKS1 open reading frame, the mutations in ACR79-5 and ACR1A3 were determined to be the replacement of Asn470 with Lys and of Leu642 with Ser in Fks1p, respectively (Fig. 1). We subcloned each of the mutated regions to wild-type FKS1 and examined the effect of each mutation in the fks1{Delta} PGAL10-FKS2 cells. In the fks1{Delta} PGAL10-FKS2 strain, FKS2 gene expression was controlled by the GAL10 promoter and suppressed in the presence of glucose. Therefore, the effect of the substitution in Fks1p can be analyzed under the depletion of endogenous Fks1p and Fks2p in the fks1{Delta} PGAL10-FKS2 cells in glucose medium. The introduction of mutated FKS1 (FKS1N470K or FKS1L642S) to the fks1{Delta} PGAL10-FKS2 strain conferred selective resistance to arborcandin C, as shown by arborcandin C-resistant mutants ACR79-5 and ACR1A3 (Table 2). Moreover, the GSs from cells with FKS1N470K or FKS1L642S conferred selective resistance to arborcandin C (Table 3). These results show that Asn470 and Leu642 of Fks1p are critical amino acids in the GS-inhibitory activity of arborcandin C and strongly suggest that the target molecule of arborcandin C is Fks1p, the putative catalytic subunit of GS.



View larger version (35K):
[in this window]
[in a new window]
 
FIG. 1. Nucleotide sequence analysis of FKS1 open reading frames of ACR79-5 and ACR1A3. (A) Partial nucleotide sequences of FKS1 from wild-type and arborcandin C-resistant mutants. Arrows, points of nucleotide mutations found in the resistant mutants. (B) Predicted amino acid sequences of Fks1p from the resistant mutants. The substituted residues in the resistant mutants are underlined.

The results we obtained also suggested that Asn470 and Leu642 in Fks1p are topologically proximate. The model of membrane topology of Fks1p was predicted by hydropathy plot analysis (6). In the model, Asn470 and Leu642 exist in the transmembrane domain and cytoplasmic loop domain, respectively, and Asn470 is topologically distant from Leu642 (Fig. 2A). On the other hand, in the model predicted by the PHDhtm server (http://cubic.bioc.columbia.edu/predictprotein), Asn470 and Leu642 exist at the first and third extracellular regions, respectively, and it is possible that these amino acid residues are close to each other (Fig. 2B). Our results support the model of Fks1p by the PHDhtm server and contribute to the understanding of the exact structure of Fks1p.



View larger version (59K):
[in this window]
[in a new window]
 
FIG. 2. Model of the predicted membrane topology of the N-terminal region of Fks1p. Solid line, polypeptide chain; boxes, putative transmembrane helices. (A) Model predicted by hydropathy plot analysis. (B) Model predicted by the PHDhtm server.

Amino acid residues corresponding to Asn470 and Leu642 and the primary structure of the regions around those amino acid residues are well conserved among arborcandin-sensitive fungi (Fig. 3). However, these amino acid residues are also conserved in Cryptococcus neoformans, which is resistant to arborcandins (14). Although C. neoformans has GS and although the unique FKS1 gene of this organism is essential for its growth (19), C. neoformans is resistant to all the known GS inhibitors (8, 12, 20). A common mechanism of resistance to these GS inhibitors, including arborcandins, may exist in C. neoformans.



View larger version (43K):
[in this window]
[in a new window]
 
FIG. 3. Amino acid sequence alignment of Fks proteins from various fungi. The amino acid sequences of S. cerevisiae Fks1p, residues 459 to 483 and 632 to 656, are aligned to the relevant sequences of Fks proteins from C. albicans, A. fumigatus, and C. neoformans (GenBank accession numbers D88815, U79728, and AF102882, respectively). Gray boxes and filled boxes, conserved residues among Fks proteins and mutated residues in arborcandin C-resistant mutants, respectively.

Isolation of the selective arborcandin C-resistant mutants and the identification of amino acids responsible for the resistance provide new insights into the interaction between Fks1p and GS inhibitors. Based on the results of this study, future studies will monitor the direct interaction between arborcandin C and the N-terminal putative extracellular region. Structural analysis of the N-terminal region of Fks1p would also help to improve the antifungal activity of arborcandins.


arrow
Nucleotide sequence accession numbers.
 
Whole nucleotide sequences of FKS1 open reading frames of the wild type, ACR79-5, and ACR1A3 are available in the GenBank database under the accession numbers AY395693, AY395694, and AY395695, respectively.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Lead Discovery Research Laboratories, Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Phone: 81-3-3492-3131. Fax: 81-3-5436-8578. E-mail: takaoo{at}shina.sankyo.co.jp. Back


arrow
REFERENCES
 
    1
  1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338.[Abstract]
  2. 2
  3. Adefarati, A. A., O. D. Hensens, E. T. Jones, and J. S. Tkacz. 1992. Pneumocandins from Zalerion arboricola. V. Glutamic acid- and leucine-derived amino acids in pneumocandin A0 (L-671,329) and distinct origins of the substituted proline residues in pneumocandins A0 and B0. J. Antibiot. 45:1953-1957.[Medline]
  4. 3
  5. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.[Abstract]
  6. 4
  7. Cabib, E., and M. S. Kang. 1987. Fungal 1,3-ß-glucan synthase. Methods Enzymol. 138:637-642.[Medline]
  8. 5
  9. Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48:471-497.[CrossRef][Medline]
  10. 6
  11. Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nielsen, A. M. Dahl, P. Mazur, W. Baginsky, W. Li, M. el-Sherbeini, J. A. Clemas, S. M. Mandala, B. R. Frommer, and M. B. Kurtz. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-ß-D-glucan synthase. Proc. Natl. Acad. Sci. USA 91:12907-12911.[Abstract/Free Full Text]
  12. 7
  13. Eng, W. K., L. Faucette, M. M. McLaughlin, R. Cafferkey, Y. Koltin, R. A. Morris, P. R. Young, R. K. Johnson, and G. P. Livi. 1994. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. Gene. 151:61-71.[CrossRef][Medline]
  14. 8
  15. Fujie, A., T. Iwamoto, H. Muramatsu, T. Okudaira, I. Sato, T. Furuta, Y. Tsurumi, Y. Hori, M. Hino, S. Hashimoto, and M. Okuhara. 2000. FR901469, a novel antifungal antibiotic from an unidentified fungus no. 11243. II. In vitro and in vivo activities. J. Antibiot. 53:920-927.[Medline]
  16. 9
  17. Guthrie, C., and G. R. Fink (ed.). 1991. Methods in enzymology, vol. 194. Guide to yeast genetics and molecular biology. Academic Press, Inc., San Diego, Calif.
  18. 10
  19. Inoue, S. B., N. Takewaki, T. Takasuka, T. Mio, M. Adachi, Y. Fujii, C. Miyamoto, M. Arisawa, Y. Furuichi, and T. Watanabe. 1995. Characterization and gene cloning of 1,3-ß-glucan synthase from Saccharomyces cerevisiae. Eur. J. Biochem. 231:845-854.[Medline]
  20. 11
  21. Klis, F. M. 1994. Review: cell wall assembly in yeast. Yeast 10:851-869.[CrossRef][Medline]
  22. 12
  23. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.[Abstract]
  24. 13
  25. Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86.[Medline]
  26. 14
  27. Ohyama, T., Y. Kurihara, Y. Ono, T. Ishikawa, S. Miyakoshi, K. Hamano, M. Arai, T. Suzuki, H. Igari, Y. Suzuki, and M. Inukai. 2000. Arborcandins A, B, C, D, E and F, novel 1,3-ß-glucan synthase inhibitors: production and biological activity. J. Antibiot. 53:1108-1116.[Medline]
  28. 15
  29. Ohyama, T., Y. Iwadate-Kurihara, T. Hosoya, T. Ishikawa, S. Miyakoshi, K. Hamano, and M. Inukai. 2002. F-10748 A1, A2, B1, B2, C1, C2, D1 and D2, novel papulacandins. J. Antibiot. 55:758-763.[Medline]
  30. 16
  31. Qadota, H., C. P. Python, S. B. Inoue, M. Arisawa, Y. Anraku, Y. Zheng, T. Watanabe, D. E. Levin, and Y. Ohya. 1996. Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-ß-glucan synthase. Science 272:279-281.[Abstract]
  32. 17
  33. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
  34. 18
  35. Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27.[Abstract/Free Full Text]
  36. 19
  37. Thompson, J. R., C. M. Douglas, W. Li, C. K. Jue, B. Pramanik, X. Yuan, T. H. Rude, D. L. Toffaletti, J. R. Perfect, and M. Kurtz. 1999. A glucan synthase FKS1 homologue in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181:444-453.[Abstract/Free Full Text]
  38. 20
  39. VanMiddlesworth, F., M. N. Omstead, D. Schmatz, K. Bartizal, R. Fromtling, G. Bills, K. Nollstadt, S. Honeycutt, M. Zweerink, G. Garrity, and K. Wilson. 1991. L-687-781, a new member of the papulacandin family of ß-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation and biological activity. J. Antibiot. 44:45-51.[Medline]


Antimicrobial Agents and Chemotherapy, January 2004, p. 319-322, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.319-322.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Katiyar, S. K., Edlind, T. D. (2009). Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 53: 1772-1778 [Abstract] [Full Text]  
  • Katiyar, S., Pfaller, M., Edlind, T. (2006). Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 2892-2894 [Abstract] [Full Text]  
  • Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohyama, T.
Right arrow Articles by Isono, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohyama, T.
Right arrow Articles by Isono, F.